Pharmaceuticals & Therapeutics

A new company emerges from Purdue Pharma's bankruptcy, owned by a non-profit and tasked with fighting the very opioid crisis its predecessor fueled.

Consumers and insurers who bought QVAR inhalers may get cash from a $35M settlement over claims Teva illegally blocked cheaper generic alternatives.

The K-beauty brand expands into Mexico's booming market, but safety claims face scrutiny as reports of adverse effects surface in other regions.

Navigating life after a stroke can be isolating. A Maywood event offers a comprehensive network of support, resources, and inspiration for the journey.

Following a year of record profits, Cipher Pharmaceuticals is renewing its share buyback program, signaling a strong belief that its stock is undervalued.

Medcura adds a Johnson & Johnson heavyweight to its board, aiming to disrupt the surgical hemostasis market with its FDA-designated breakthrough gel, LifeGel.

A $1M grant funds research into an ultra-rare cancer's defense mechanism, offering new hope against a disease with a grim 10% survival rate.

Medtech firm TELA Bio overhauls its board with M&A and turnaround experts, signaling a major strategic shift to accelerate growth and escape losses.

Eli Lilly begins a crucial Phase 2 study for a novel, non-addictive pain drug from Confo Therapeutics, a major step in the hunt for an opioid alternative.

PVP Labs' new drug offers potent pain relief without addiction risk. A landmark DEA ruling clears it as a non-controlled substance, set to reshape medicine.

Wellspect HealthCare's new Surity™ catheter targets a growing market, offering a non-invasive solution designed for comfort, discretion, and dignity.

A new imaging agent could slash the years-long diagnostic delay for endometriosis, offering hope to millions of women suffering from the debilitating condition.

Swiss medtech firm CorFlow is tackling a major post-heart attack complication with two pivotal trials, aiming to create a new standard of care.

Former HHS Secretary Tommy Thompson joins Vector Science & Therapeutics, leveraging his political clout to advance a novel transdermal drug delivery platform.

South Korea approves its first homegrown CAR-T therapy, a landmark achievement offering new hope for lymphoma patients with impressive response rates.

After a turbulent year, Valerio Therapeutics unveils a radical new strategy focused on its V-Body platform, a new subsidiary, and strict cost controls.

A novel immunotherapy that freezes and infuses tumors shows an 87% response rate in advanced prostate cancer, aiming to turn local treatment into a systemic attack.

As AI accelerates drug approvals, a new bottleneck emerges. Firms like Totaligent are betting on the infrastructure needed to get therapies to patients.

With a new General Counsel known for navigating complex deals, Cosette Pharmaceuticals signals a major push for acquisitions and portfolio growth.

Berlin-based Tacalyx is advancing its lead drug, TCX-201, to the clinic, targeting a novel class of antigens once thought impossible to drug.